KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palvella Therapeutics (PVLA) EBIT (2016 - 2026)

Palvella Therapeutics has reported EBIT over the past 10 years, most recently at -$12.2 million for Q3 2022.

  • Quarterly EBIT rose 36.0% to -$12.2 million in Q3 2022 from the year-ago period, while the trailing twelve-month figure was -$43.0 million through Sep 2022, up 19.32% year-over-year, with the annual reading at -$38.6 million for FY2025, 954.41% down from the prior year.
  • EBIT was -$12.2 million for Q3 2022 at Palvella Therapeutics, up from -$12.3 million in the prior quarter.
  • Over five years, EBIT peaked at -$1.3 million in Q4 2019 and troughed at -$19.0 million in Q3 2021.
  • The 5-year median for EBIT is -$10.7 million (2019), against an average of -$9.2 million.
  • Year-over-year, EBIT soared 89.48% in 2019 and then crashed 833.16% in 2020.
  • A 5-year view of EBIT shows it stood at -$12.6 million in 2018, then soared by 89.48% to -$1.3 million in 2019, then crashed by 833.16% to -$12.4 million in 2020, then rose by 11.38% to -$11.0 million in 2021, then dropped by 10.63% to -$12.2 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's EBIT are -$12.2 million (Q3 2022), -$12.3 million (Q2 2022), and -$7.5 million (Q1 2022).